Ligosan Slow Release

Doxycycline hyclate, the active ingredient in Ligosan Slow Release, is a tetracycline antibiotic presented as a slow‑release formulation for periodontal use. It is employed to treat periodontal disease and chronic periodontitis by targeting the bacterial pathogens that contribute to gum inflammation and tissue loss.

GNH USA supplies Ligosan Slow Release as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Ligosan Slow Release (doxycycline hyclate) is used in the management of periodontal infections, targeting bacterial colonisation in the oral cavity.

Periodontal disease: reduces bacterial load and helps control gum inflammation. Chronic periodontitis: slows progression of tissue destruction and supports periodontal therapy.

Adverse reactions to Ligosan Slow Release may vary in frequency and severity.

Common Side Effects: - Nausea or upset stomach - Increased sensitivity to sunlight (photosensitivity) - Esophageal irritation or ulceration

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic dysfunction or jaundice

When prescribing Ligosan Slow Release, several safety considerations should be observed. - Pregnancy: category D, use only if benefits outweigh risks. - Breastfeeding: doxycycline may be excreted in milk; assess infant risk. - Renal impairment: monitor renal function and adjust therapy if required. - Sun exposure: advise patients to use sunscreen and protective clothing. - Concomitant medications: review for potential interactions before initiating therapy. - Store at below 25°C: keep in the original container, protect from moisture and light.

Ligosan Slow Release can affect the plasma levels or activity of several co‑administered medicines.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: markedly reduce doxycycline absorption. - Oral iron supplements: decrease bioavailability of the antibiotic. - Warfarin: may potentiate anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - Oral contraceptives: doxycycline may reduce hormonal efficacy. - Retinoids (e.g., isotretinoin): combined use raises risk of intracranial hypertension. - Cyclosporine: may increase cyclosporine serum concentrations.